INTRODUCTION
We have previously demonstrated that bradykinin, phorbol 12-myristate 13-acetate (PMA) and, to a substantially lesser extent, platelet-derived growth factor (PDGF), stimulate cyclic AMP formation in serum-depleted cultured airway smooth-muscle cells via a protein kinase C (PKC)-dependent pathway and, for bradykinin, the magnitude of the response limits the activation of extracellular-signal-regulated kinase-2 (ERK-2) [1, 2] . The inhibition of adenylate cyclase, by using a P-site-specific inhibitor, deoxyadenosine, enabled bradykinin to stimulate sustained activation of ERK-2 with similar kinetics to that induced by PDGF [2] . The PKC-dependent activation of adenylate cyclase appears to be down-stream ofphosphatidylcholine-specific phospholipase D (PLD) [1, 2] . The role of PLD activity in early mitogenic signalling is controversial, with both supporting and conflicting evidence [3] [4] [5] [6] . However, in airway smooth muscle, bradykinin does not support mitogenesis, but stimulates phosphatidylcholine-specific PLD activity [7] [8] [9] , and this further questions the role of PLD as an early signalling event in the initiation of proliferation in this cell type.
Activation of adenylate cyclase by PKC can be amplified by constitutive activation of the stimulatory G-protein G. [1, 2] . In this regard, the co-incident PKC-sensitive signal detector type II adenylate cyclase is expressed as a 11O/112 kDa protein in serum-depleted cell membranes [2] . The 
Cell culture
Primary cultures of guinea-pig airway smooth-muscle cells were prepared as described previously [7] . The cells were maintained in Dulbecco's modified Eagle's medium (DME) containing 10% (v/v) fetal-calf serum (FCS) and 10 % (v/v) donor horse serum (DHS) and were passaged twice, by using trypsin, before experimentation. Cells were grown to confluence on 24-or 6-well plates and routinely used 14-21 days after the initial preparation. Their identity was confirmed to be smooth muscle by showing the presence of a-actin using a smooth-muscle-specific mouse anti-a-actin monoclonal antibody [7] .
Cyclic AMP and PLD assays Cells were placed in fresh DME containing either 10% (v/v) Incubations were terminated by precipitation of the cells in 80 % (v/v) ethanol. Samples were harvested and centrifuged at 14000 g, and cyclic AMP was extracted into ethanol, which was then freeze-dried. Samples were taken for cyclic AMP determination by using the cyclic-[3H]AMP-binding assay with bovine heart cyclic-AMP-binding protein that had been purified by us as described by Rubin et al. [11] .
PLD assays were performed as described by Pyne and Pyne [7] .
Thymidine incorporation
Cells (70 80 % confluent) were placed in DME containing 0. (Table 1) , despite the ability of PKC to activate adenylate cyclase activity in these cells [1] . This is probably due to a high expression of cyclic AMP phosphodiesterase activity, which can effectively down-regulate the cyclic AMP signal [12] . However, coincident activation of G. by pre-treating cells with cholera toxin (0.5 ng/ml, 18 h) can amplify the stimulation of adenylate cyclase by PKC and enables an increase in cyclic AMP mass to be detected ( Detection of ERK ERK-l and -2 were detected as 45 and 42 kDa proteins respectively on immunoblots of electrophoresed cell lysates ( Figure  1 ). The challenge of serum-depleted cells with maximal stimulating concentrations of bradykinin (1 ,tM) provoked only the partial activation of the available pool of ERK-2 ( Figure la) . It has previously been demonstrated that phosphorylation and activation of ERK-2 results in its retarded mobility on SDS/ PAGE [13] [14] [15] [16] , and this can be observed on immunoblots (Figure la) . Surprisingly, ERK-1 did not display an electrophoretic mobility shift in response to bradykinin, even though in some cases we have detected a mobility shift in lysates isolated from cells pre-treated with PDGF (results not shown). However, our inability to observe shifts in ERK-1 consistently may be due to the experimental conditions of our SDS/PAGE. The PKC-sensitive cyclic AMP pool can inhibit the signal pathway that leads to ERK-2 activation in response to bradykinin. This was achieved by demonstrating that the bradykininstimulated ERK-2 response can be completely blocked in serumdepleted cells pre-treated with cholera toxin (0.5 ng/ml, 18 h; Table 4 Effect of growth serum on basal and forskolin-stimulated intracellular cyclic AMP formation in cholera-toxin-treated airway smooth- AMP-sensitivity of the signal pathways that do allow bradykinin to stimulate ERK-2 partially under normal conditions remained unresolved. This is important, since multiple signal pathways can lead to the activation of ERK-2. For instance, ERK-2 can be activated down-stream of (i) other PKC isoforms, (ii) Raf-l kinase and (iii) MEK kinase (ERK-kinase kinase) [13] [14] [15] . Furthermore, G-protein-linked and growth factor receptors may differentially regulate these pathways. However, for bradykinin it is possible that each of these pathways contribute to the activation of ERK-2 activity. The cyclic AMP sensitivity of these pathways is only now being assessed. Indeed, cyclic AMPdependent protein kinase can catalyse phosphorylation of Raf-1 and prevent its association with p21ra8 [16, 17] , and this leads to the down-stream blockade of ERK-2 activation. Therefore it is possible that, if one of these pathways is insensitive to cyclic AMP, it could account for the proportion of ERK-2 that is activated by bradykinin. The other pathways could then integrate at the level of ERK-2, once adenylate cyclase is blocked. However, the ability of cholera toxin to ablate the activation of ERK-2 by bradykinin, while enabling the coincident signals (G,a and PKC) to be detected and integrated by adenylate cyclase, indicates that this does not appear to be the case, and supports the concept that it is the size of the cyclic AMP response that determines the magnitude and kinetics of ERK-2 activation in this case.
The effect of deoxyadenosine is to convert the non-mitogenic agonist, bradykinin, into one that can support mitogenesis. This is not immediately obvious from our previous study [2] , showing that full sustained activation of ERK-2 is also achieved under these conditions, particularly as the latter requirement for mitogenesis is not unequivocally proven. Therefore, to our knowledge, this is the first demonstration describing such conversion of an agonist and indicates that its mitogenicity is determined, in part, by its ability to activate an endogenous inhibitory cyclic AMP signal pathway.
Type 11 adenylate cyclase regulation: effect of serum The mechanism of blockade of PKC-sensitive activation of adenylate cyclase in serum-stimulated cells remains to be fully characterized, but may be an adaptive mechanism which enables cells to progress into the cell cycle by allowing unimpeded ERK activation. The lesion is not at the level of PLD. From our previous studies, the activation of PLD by bradykinin appears to involve a novel bradykinin receptor type, extracellular Ca2+ and PKC activity [7, 8] . We do not know as yet whether the PKC that regulates PLD activity can also modulate adenylate cyclase, although presumbly this is not the case, given the requirement of adenylate cyclase activity for prior PLD activation. Nevertheless, none of the signal components regulating PLD appears to be altered by serum. Therefore, we speculate that the lesion occurs between adenylate cyclase and PKC. Whether, this involves the induction of a serum-factor-dependent tyrosine kinase that is capable of modifying the signal coupling remains to be determined.
Conclusion
The cyclic AMP response pathway can be negatively modulated by serum factors, although the full significance on mitogenesis requires further study. New evidence is presented, demonstrating that integration of both PKC and Gs signals by adenylate cyclase can dramatically affect ERK-2 activation kinetics and DNA synthesis, and this may have an important physiological implication for the amplification of PKC-stimulated signals by G,-linked receptor agonists and the consequent regulation of mitogenesis.
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